Petco Health & Wellness Company, Inc.
For the period ended Feb 1, 2025. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2025
WOOF$3.10+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
| Common stock | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Class A (shares) | Class B-1 (shares) | Class B-2 (shares) | Amount | Additional paid-in capital | Retained earnings (accumulateddeficit) | Accumulatedothercomprehensive(loss) income | Totalstockholders’ equity | Noncontrollinginterest | Totalequity | |
| Balance at January 29, 2022 | 227,187 | 37,791 | 37,791 | $265 | $2,133,821 | $142,166 | $(2,238) | $2,274,014 | $(18,195) | $2,255,819 |
| Equity-based compensation expense (Note 11) | — | — | — | — | 61,355 | — | — | 61,355 | — | 61,355 |
| Net income | — | — | — | — | — | 90,801 | — | 90,801 | (891) | 89,910 |
| Foreign currency translation adjustment, net of tax of $71 | — | — | — | — | — | — | 194 | 194 | — | 194 |
| Unrealized loss on derivatives, net of tax of $(714) (Note 8) | — | — | — | — | — | — | (2,180) | (2,180) | — | (2,180) |
| Losses on derivatives reclassified to income, net of tax of $42 (Note 8) | — | — | — | — | — | — | 126 | 126 | — | 126 |
| Investment in veterinary joint venture, net of tax of $(13,774) (Note 1) | — | — | — | — | (40,312) | — | — | (40,312) | 19,086 | (21,226) |
| Issuance of common stock, net of tax withholdings | 1,151 | — | — | 1 | (2,522) | — | — | (2,521) | — | (2,521) |
| Balance at January 28, 2023 | 228,338 | 37,791 | 37,791 | $266 | $2,152,342 | $232,967 | $(4,098) | $2,381,477 | $— | $2,381,477 |
| Equity-based compensation expense (Note 11) | — | — | — | — | 82,680 | — | — | 82,680 | — | 82,680 |
| Net loss | — | — | — | — | — | (1,280,210) | — | (1,280,210) | — | (1,280,210) |
| Foreign currency translation adjustment, net of tax of $1,932 | — | — | — | — | — | — | 5,534 | 5,534 | — | 5,534 |
| Unrealized gain on derivatives, net of tax of $246 (Note 8) | — | — | — | — | — | — | 752 | 752 | — | 752 |
| Gains on derivatives reclassified to income, net of tax of $(120) (Note 8) | — | — | — | — | — | — | (367) | (367) | — | (367) |
| Issuance of common stock, net of tax withholdings | 2,818 | — | — | 3 | (5,440) | — | — | (5,437) | — | (5,437) |
| Balance at February 3, 2024 | 231,156 | 37,791 | 37,791 | $269 | $2,229,582 | $(1,047,243) | $1,821 | $1,184,429 | $— | $1,184,429 |
| Equity-based compensation expense (Note 11) | — | — | — | — | 50,188 | — | — | 50,188 | — | 50,188 |
| Net loss | — | — | — | — | — | (101,816) | — | (101,816) | — | (101,816) |
| Foreign currency translation adjustment, net of tax of $(7,605) | — | — | — | — | — | — | (21,836) | (21,836) | — | (21,836) |
| Unrealized gain on derivatives, net of tax of $1,418 (Note 8) | — | — | — | — | — | — | 4,303 | 4,303 | — | 4,303 |
| Gains on derivatives reclassified to income, net of tax of $(776) (Note 8) | — | — | — | — | — | — | (2,371) | (2,371) | — | (2,371) |
| Issuance of common stock, net of tax withholdings | 7,910 | — | — | 8 | 725 | — | — | 733 | — | 733 |
| Balance at February 1, 2025 | 239,066 | 37,791 | 37,791 | $277 | $2,280,495 | $(1,149,059) | $(18,083) | $1,113,630 | $— | $1,113,630 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.